Drugs Made In America II Files S-1/A for $500M Pharma SPAC IPO

TL;DR

**DMIIU is a high-risk SPAC with significant founder dilution and potential conflicts of interest, making it a speculative bet on a future pharma acquisition.**

AI Summary

Drugs Made In America Acquisition II Corp. (DMIIU) filed an S-1/A on September 5, 2025, for an initial public offering of 50,000,000 units at $10.00 per unit, aiming to raise $500,000,000. Each unit comprises one ordinary share and one right to receive one-tenth of an ordinary share upon business combination. The SPAC intends to focus its search for business combination targets within the pharmaceutical industry. The sponsor, Drugs Made In America Acquisition II LLC, and Cantor Fitzgerald & Co. will purchase an aggregate of 1,200,000 private units for $12,000,000. Public shareholders face immediate and substantial dilution due to the sponsor acquiring 14,375,000 founder shares for a nominal price of $35,000. The company will deposit $500,000,000 into a trust account, which will not be released until a business combination or redemption event. The company has up to 24 months to complete an initial business combination, or it will redeem 100% of public shares.

Why It Matters

This S-1/A filing signals a new SPAC entering the competitive pharmaceutical M&A landscape, offering investors a chance to participate in a potential industry consolidation play. For employees and customers of a future target, it could mean access to public market capital for growth and innovation. However, the significant dilution for public shareholders and potential conflicts of interest from management, who also lead another SPAC (DMAA), warrant careful consideration. The success of this offering will test investor appetite for blank-check companies focused on a specific, capital-intensive sector.

Risk Assessment

Risk Level: high — The filing explicitly states, "Investing in our securities involves a high degree of risk." Public shareholders will incur "immediate and substantial dilution" because the sponsor acquired 14,375,000 founder shares for a nominal price of $35,000. Additionally, management faces conflicts of interest, as officers and directors also serve DMAA, another SPAC searching for targets, potentially diverting opportunities.

Analyst Insight

Investors should approach DMIIU with extreme caution, recognizing the substantial dilution and inherent conflicts of interest. Await further details on a potential target business before committing capital, as the current offering is highly speculative and relies heavily on the management team's ability to identify and execute a value-accretive pharmaceutical acquisition.

Financial Highlights

debt To Equity

0.0

revenue

$0

operating Margin

0%

total Assets

$500,000,000

total Debt

$0

net Income

$0

eps

$0

gross Margin

0%

cash Position

$500,000,000

revenue Growth

+0%

Key Numbers

• $500,000,000 — Gross proceeds from public offering (Amount to be raised from 50,000,000 units at $10.00 each)
• 50,000,000 — Units offered (Number of units in the initial public offering)
• $10.00 — Offering price per unit (Price for each unit in the initial public offering)
• 1,200,000 — Private units purchased by sponsor and Cantor (Aggregate number of private units purchased at $10.00 per unit)
• $12,000,000 — Aggregate cost of private units (Total investment by sponsor and Cantor for private units)
• 14,375,000 — Founder shares held by sponsor (Shares acquired by the sponsor for a nominal price)
• $35,000 — Cost of founder shares (Nominal price paid by the sponsor for 14,375,000 founder shares)
• 24 months — Time to complete business combination (Maximum period allowed from closing of offering to complete an initial business combination)
• $325,000 — Loans to be repaid to sponsor (Maximum amount of offering-related and organizational expense loans to be repaid upon offering consummation)
• $10,000 — Monthly reimbursement to sponsor (Amount reimbursed for office space, utilities, and administrative support)

Key Players & Entities

• Drugs Made In America Acquisition II Corp. (company) — Registrant and blank check company
• Lynn Stockwell (person) — Chief Executive Officer and Executive Chair of Drugs Made In America Acquisition II Corp. and Drugs Made In America Acquisition Corp.
• Drugs Made In America Acquisition II LLC (company) — Sponsor of Drugs Made In America Acquisition II Corp.
• Cantor Fitzgerald & Co. (company) — Representative of the underwriters
• U.S. Securities and Exchange Commission (regulator) — Regulatory body for the S-1/A filing
• Continental Stock Transfer & Trust Company (company) — Trustee for the trust account
• Loeb & Loeb LLP (company) — Legal counsel for the registrant
• Ellenoff Grossman & Schole LLP (company) — Legal counsel for the registrant
• The Nasdaq Global Market (company) — Intended listing exchange for DMIIU units
• Drugs Made In America Acquisition Corp. (company) — Another SPAC where DMIIU's management serves

FAQ

Risk Factors

• Redemption of Public Shares [high — financial]: If DMIIU fails to complete a business combination within 24 months, public shareholders will have their shares redeemed. This redemption will occur at a per-share price equal to the aggregate amount of the net proceeds from the offering and the exercise of warrants, divided by the number of public shares sold in the offering. This redemption mechanism poses a risk to investors if a suitable target is not identified within the timeframe.
• Dilution from Sponsor Shares [high — financial]: The sponsor acquires 14,375,000 founder shares for a nominal price of $35,000, representing a significant portion of the total shares. This structure leads to immediate and substantial dilution for public shareholders upon the completion of the offering, as the sponsor's effective cost per share is substantially lower.
• Trust Account Limitations [medium — financial]: The $500,000,000 raised will be deposited into a trust account and will not be released until a business combination or redemption event occurs. This means the funds are inaccessible for operational expenses or early-stage development prior to a merger, potentially limiting the company's flexibility.
• Sponsor Loan Repayment [medium — financial]: The company may repay up to $325,000 in offering-related and organizational expense loans to the sponsor upon the offering's consummation. Additionally, the sponsor will be reimbursed $10,000 per month for office space, utilities, and administrative support. These payments represent an immediate outflow of capital that could otherwise be used for business development.
• Competition in Pharmaceutical SPACs [medium — market]: The pharmaceutical industry is highly competitive, and DMIIU's focus on this sector means it will face numerous established players and other SPACs seeking targets. The success of the business combination depends on identifying an undervalued or strategically advantageous target amidst this competition.
• Regulatory Scrutiny of Pharmaceutical Targets [high — regulatory]: The pharmaceutical industry is subject to extensive regulatory oversight from bodies like the FDA. Any target company will need to navigate complex approval processes, compliance requirements, and potential changes in healthcare policy, which can impact valuation and future prospects.

Industry Context

The pharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies in this sector face intense competition from both established giants and emerging biotechs. Trends include a focus on personalized medicine, advancements in gene therapy and biologics, and increasing pressure on drug pricing.

Regulatory Implications

As DMIIU intends to target the pharmaceutical industry, any potential business combination will be subject to stringent regulatory review by agencies like the FDA. Compliance with manufacturing standards, clinical trial protocols, and marketing regulations is paramount and can significantly impact a target company's valuation and operational viability.

What Investors Should Do

1. Evaluate the sponsor's track record and expertise in the pharmaceutical sector.
2. Assess the potential for dilution from founder shares and private units.
3. Monitor the timeline for business combination completion.
4. Analyze the competitive landscape for pharmaceutical acquisition targets.

Key Dates

• 2025-09-05: S-1/A Filing — Initiates the public offering process, providing detailed information about the SPAC's structure, objectives, and risks to potential investors.

Glossary

SPAC

Special Purpose Acquisition Company. A shell company that raises capital through an IPO to acquire an existing company. (DMIIU is a SPAC, and its primary purpose is to find and merge with a target company in the pharmaceutical industry.)

Units

A combination of securities sold together in an offering, typically including shares and warrants or rights. (DMIIU is offering units, each consisting of one ordinary share and one-tenth of a right, at $10.00 per unit.)

Rights

A type of security that gives the holder the right, but not the obligation, to purchase additional securities, often at a specified price. (Each unit includes a right to receive one-tenth of an ordinary share upon a business combination, impacting potential future share count.)

Founder Shares

Shares issued to the SPAC's sponsor prior to the IPO, typically at a nominal price, and often subject to vesting or transfer restrictions. (The sponsor holds 14,375,000 founder shares acquired for $35,000, indicating significant dilution for public investors.)

Trust Account

An account where IPO proceeds are held in escrow until a business combination is completed or the SPAC liquidates. (The $500,000,000 raised will be placed in a trust account, safeguarding investor capital until a merger or redemption.)

Business Combination

The merger or acquisition of the SPAC with a target operating company. (DMIIU has 24 months to identify and complete a business combination with a pharmaceutical company.)

Redemption

The process by which public shareholders can elect to have their shares repurchased by the SPAC, typically at the IPO price, if a business combination is not completed. (Public shareholders can redeem their shares if DMIIU fails to complete a business combination within the specified timeframe.)

Year-Over-Year Comparison

As this is an S-1/A filing for an initial public offering, there is no prior year filing to compare against. Key metrics such as revenue, net income, and margins are not yet applicable as the company is a shell entity focused on raising capital for a future acquisition.

Key Financial Figures

• $500,000,000 — MBER 5, 2025 PRELIMINARY PROSPECTUS $500,000,000 Drugs Made In America Acquisition II
• $10.00 — ies. Each unit has an offering price of $10.00 and consists of one ordinary share and
• $100,000 — that may be due or payable), and up to $100,000 of interest to pay dissolution expenses
• $12,000,000 — units" at a price of $10.00 per unit ( $12,000,000 in the aggregate) in a private placemen
• $35,000 — dinary shares (which were purchased for $35,000 and which we refer to as "founder share
• $10,000 — burse our sponsor in an amount equal to $10,000 per month for office space, utilities a
• $325,000 — n of this offering, we will repay up to $325,000 in loans made to us by our sponsor to c
• $0.20 — 472,500,000 ____________ (1) Includes $0.20 per unit (excluding any units sold purs
• $10,000,000 — derwriters' over -allotment option), or $10,000,000 in the aggregate (whether or not the un
• $0.35 — closing of this offering. Also includes $0.35 per unit on units other than those sold
• $0.55 — nderwriters' over -allotment option and $0.55 per unit on units sold pursuant to the
• $17,500,000 — nderwriters' over -allotment option, or $17,500,000 in the aggregate or up to $21,625,000 i
• $21,625,000 — r $17,500,000 in the aggregate or up to $21,625,000 in the aggregate if the underwriters' o
• $500 m — ate units described in this prospectus, $500 million, or $575 million if the underwrit
• $575 million — ed in this prospectus, $500 million, or $575 million if the underwriters' over -allotment op

Filing Documents

• ea0234544-06.htm (S-1/A) — 4458KB
• ea023454406ex1-1_drugs.htm (EX-1.1) — 245KB
• ea023454406ex5-1_drugs2.htm (EX-5.1) — 38KB
• ea023454406ex5-2_drugs2.htm (EX-5.2) — 11KB
• ea023454406ex23-1_drugs2.htm (EX-23.1) — 2KB
• ex5-1_001.jpg (GRAPHIC) — 11KB
• ex5-1_002.jpg (GRAPHIC) — 12KB
• ex5-2_001.jpg (GRAPHIC) — 13KB
• 0001213900-25-085167.txt ( ) — 7718KB
• ck0002040475-20250905.xsd (EX-101.SCH) — 9KB
• ck0002040475-20250905_def.xml (EX-101.DEF) — 13KB
• ck0002040475-20250905_lab.xml (EX-101.LAB) — 117KB
• ck0002040475-20250905_pre.xml (EX-101.PRE) — 68KB
• ea0234544-06_htm.xml (XML) — 942KB

Risk factors

Risk factors 41 Cautionary note regarding forward-looking statements 82

Use of proceeds

Use of proceeds 84 Dividend policy 88

Dilution

Dilution 89 Capitalization 93

Management's discussion and analysis of financial condition and results of operations

Management's discussion and analysis of financial condition and results of operations 94 Proposed business 100 Management 127 Principal shareholders 137 Certain relationships and related party transactions 140

Description of securities

Description of securities 143 MATERIAL United states federal income tax considerations 157

Underwriting

Underwriting 166 Legal matters 176 Experts 176 Where you can find additional information 176 Index to Financial Statements F-1 This prospectus contains references to trademarks and service marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the or symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companies' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. i Table of Contents Summary This summary only highlights the more detailed information appearing elsewhere in this prospectus. As this is a summary, it does not contain all of the information that you should consider in making an investment decision. You should read this entire prospectus carefully, including the information under "Risk Factors" and our financial statements and the related notes included elsewhere in this prospectus, before investing. General Drugs Made In America Acquisition II Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses, which we refer to throughout this prospectus as our "initial business combination." To date, our efforts have been limited to organizational activities as well as activities related to this offering. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business

View Full Filing

View this S-1/A filing on SEC EDGAR